High expression of apoptosis protein (Api-5) in chemoresistant triple-negative breast cancers: an innovative target

November 25, 2019

The cover for issue 61 of Oncotarget features Figure 4, "The influence of stress conditions on API-5 expression and inhibition," by Bousquet, et al.

78 TNBC biopsies from patients with different responses to chemotherapy were analysed for API-5 expression before any treatment.

Further studies on API-5 expression and inhibition were performed on patient-derived TNBC xenografts, one highly sensitive to chemotherapies and the other resistant to most tested drugs.

Clinical analyses of the 78 TNBC biopsies revealed that API-5 was more markedly expressed in endothelial cells before any treatment among patients with chemoresistant TNBC, and this was associated with greater micro-vessel density.

Dr. Melanie Di Benedetto and Dr. Guilhem Bousquet said, "Apoptosis Inhibitor-5 (API-5) also called Anti-Apoptosis Clone 11 (AAC-11) is a 58-kDa nuclear protein highly conserved across species."

API-5 was originally identified as an anti-apoptotic protein in mouse fibroblasts and in human cervical carcinoma cell lines, in which API-5 significantly enhanced cell survival after serum deprivation or ultraviolet sensitization.

In vitro, a decrease in API-5 expression sensitized human cancer cell lines to apoptosis, and increased their sensitivity to anticancer drugs.

In human osteocarcinoma cells, API-5 promotes survival through the inhibition of an E2 promoter-binding factor, and the integrity of the leucine zipper domain is required for the anti-apoptotic functions of API-5.

Previous authors engineered an anti-API5 peptide composed of the LZ domain fused with the Antennapedia/Penetrating protein domain since the integrity of this domain is essential for the function of API-5. This LZ peptide is able to penetrate cells in vitro, and to cancel the API-5/acinus interaction.

In this pre-clinical study, the authors studied the expression of API-5 in patients with chemotherapy-resistant TNBC and the inhibition of API-5 in a resistant TNBC xenograft model.

The Benedetto/Bousquet Research Team concluded that Hypoxia is associated with drug resistance and they have previously demonstrated a link between cancer stem-cells, hypoxic niches and resistance to sunitinib in renal cell carcinoma.

In vivo, hypoxia has been shown to induce resistance to apoptosis in human cervical cancer cell lines through a selection of p53-mutated cells.
-end-
Full text - https://doi.org/10.18632/oncotarget.27312

Correspondence to - Melanie Di Benedetto - melanie.dibenedetto@univ-paris13.fr and Guilhem Bousquet - guilhem.bousquet@aphp.fr

Keywords - triple-negative breast cancer, chemotherapy resistance, apoptosis-inhibitor-5, peptide, anti-angiogenic therapy

About Oncotarget

Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

To learn more about Oncotarget, please visit http://www.oncotarget.com or connect with @OncotargetJrnl

Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

Media Contact
18009220957x105
MEDIA@IMPACTJOURNALS.COM

Impact Journals LLC

Related Apoptosis Articles from Brightsurf:

Thymoquinone induces apoptosis & DNA damage in 5-Fluorouracil-resistant colorectal cancer
Volume 11, Issue 31 from @Oncotarget reported that TQ decreased the expression levels of colorectal stem cell markers CD44 and Epithelial Cell Adhesion Molecule Ep CAM and proliferation marker Ki67 in colonospheres derived from both cell lines and reduced cellular migration and invasion.

Oncotarget: Th1 cytokines potentiate apoptosis of breast cancer cells and suppress tumor growth
Volume 11, Issue 30 of Oncotarget reported that previously, the authors showed that anti-estrogen drugs combined with a dendritic cell-based anti-HER-2 vaccine known to induce strong Th1-polarized immunity dramatically improved clinical response rates in patients with HER-2pos/ERpos early breast cancer.

Opening an autophagy window as the apoptosis door starts to close
Tokyo Medical and Dental University (TMDU) researchers have successfully attached the cancer cell-targeting antibody Trastuzumab to a previously reported supermolecule that induces autophagic cell death.

Stop Livin to make lymphoma cells stop living
Researchers at the University of Tsukuba have shown that the protein Livin, an inhibitor of apoptosis or programmed cell death, mediates resistance to immunotherapy in some lymphoma variants.

Protein causes mutations that lead to breast cancer cell aggression
In her previous research, University of Alberta biochemist Ing Swie Goping identified that the protein, BCL-2 interacting killer (BIK), was associated with relapses in breast cancer patients.

Shigella prevents infected cells from sacrificing themselves for the greater good
Researchers from Tokyo Medical and Dental University (TMDU) investigated how Shigella survive and multiply to cause severe inflammatory colitis.

Bacteria can 'outsmart' programmed cell death
To be able to multiply, bacteria that cause diarrhoea block mediators of programmed cell death, a new study in 'Nature Microbiology' shows.

High expression of apoptosis protein (Api-5) in chemoresistant triple-negative breast cancers: an innovative target
78 TNBC biopsies from patients with different responses to chemotherapy were analysed for API-5 expression before any treatment.

High expression of apoptosis protein (Api-5) in chemoresistant triple-negative breast cancers
78 TNBC biopsies from patients with different responses to chemotherapy were analysed for API-5 expression before any treatment.

Researchers describe a mechanism inducing self-killing of cancer cells
A KAIST research team has developed helical polypeptide potassium ionophores that lead to the onset of programmed cell death.

Read More: Apoptosis News and Apoptosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.